|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 自发性脑出血管理指南 美国心脏协会/美国卒中协会针对医疗专业人员的指南显示文摘目的本指南旨在为自发性脑出血的诊断和治疗提供最新的全面推荐意见。方法利用PubMed进行规范化文献检索,检索时间至2013年8月底。撰写委员会成员通过远程电信会议讨论指南内容及推荐意见,采用美国心脏协会/美国卒中协会的疗效确定性水平和证据分级方案对推荐意见进行分级。由6位同行评议专家以及卒中委员会科学声明监督委员会和卒中委员会领导委员会成员对指南草案进行发表前审阅。结果本文为急性脑出血患者的医疗诊治提供了循证指南,重点包括诊断、凝血功能障碍和血压管理、继发性脑损伤防治、颅内压控制、外科治疗的作用、转归预测、康复、二级预防以及将来需要考虑的问题。本指南已纳入最新的3期临床试验结果。结论脑出血是一种需要进行早期积极救治的危重疾病。本指南为脑出血患者的目标导向治疗提供了一个框架。 | J. Claude Hemphill Ⅲ Steven M. Greenberg Craig S. Anderson Kyra Beckelr Bernard R. Bendok Mary Cushman Gordon L. Fung Joshua N. Goldstein R. LochMacdonald Pamela H Mitchell, Phillip A Scott,Magdy H Selim, Daniel Woo 高圆圆 徐欣 | 2015 | 国际脑血管病杂志2015，23，10： | 444 |
| 2 | GRADE:证据质量和推荐强度分级的共识显示文摘GRADE工作组致中国读者:推荐分级的评估、制定与评价(GRADE)工作组已取得长足进步。我们制定了系列指南文件,除发表文章外,该非正式组织已经发展成为一个评价证据、转化卫生保健领域知识用以指导决策者的智囊团。80余位国际专家研究和制定了该评价系统。正如其他科学一样,证据评价和指南制定科学不会停滞不前。经过十年发展,GRADE的工作将借助中国Cochrane中心的推广在中国的卫生保健领域更加广为人知。GRADE工作组的成员期待与中国的指南制定组织、方法学家、临床医生和决策者合作,实现我们的共同目标:人人享有更好的卫生保健。中国Cochrane中心翻译GRADE工作组在BMJ上发表的系列文章,是朝这个方向迈出的重要一步,也是对下一步在中国推广GRADE工作的直接贡献。感兴趣的读者可登录我们的网站www.gradeworkinggroup.org和在以下网址获取我们的软件GRADEprohttp://gffzz73f9075754ca43bbhnvpxpxqffkqp6bnp.ffgz.tsg.suse.edu.cn. | Gordon H Guyatt Andrew D Oxman Gunn E Vist Regina Kunz Yngve Falck-Ytter Pablo Alonso-Coello Holger J Schünemann GRADE工作组 陈佩贤 陈耀龙 李幼平 | 2009 | 中国循证医学杂志2009，9，1： | 60 |
| 3 | GRADE:从证据到推荐显示文摘GRADE系统将指南中的推荐分为强弱两级。本文旨在探索这种分级的含义及对患者、临床医生、政策制定者各自的意义。 | Gordon H Guyatt Andrew D Oxman Regina Kunz Yngve Falck-Ytter Gunn E Vist Alessandro Liberati Holger J Schünemann 谭培勇 陈耀龙 李幼平 | 2009 | 中国循证医学杂志2009，9，3： | 26 |
| 4 | 意见不一致时的策略:应用GRADE网格对临床实践指南达成共识显示文摘指南制定委员会的结构庞大和多元化使达成共识变得困难。Roman Jaeschke及其同事阐述了一种达成共识的简单方法,即当无法取得一致时,应用GRADE网格对临床实践指南达成共识。 | Roman Jaeschke Gordon H Guyatt Phil Dellinger Holger Schünemann Mitchell M Levy Regina Kunz Susan Norris Julian Bion 刘芳 陈耀龙 | 2009 | 中国循证医学杂志2009，9，7： | 22 |
| 5 | GRADE:什么是“证据质量”?为什么它对临床医生重要?显示文摘指南制定者们利用各式各样的系统对证据质量进行分级,并据此给出他们的推荐意见。但这些分级系统有些过于简单,有的不易理解,还有的尽管详细却很复杂。 | Gordon H Guyatt Andrew D Oxman Regina Kunz Gunn E Vist Yngve Falck-Ytter Holger J Schünemann 陈柳 陈耀龙 李幼平 | 2009 | 中国循证医学杂志2009，9，2： | 12 |
| 6 | 绿激光前列腺汽化(PVP)治疗前列腺癌导致的下尿路梗阻降低前列腺癌播散危险性的临床研究显示文摘目的验证绿激光前列腺汽化(PVP)可以降低治疗前列腺癌导致的下尿路梗阻过程中前列腺癌细胞播散入血液循环的危险性。方法4例前列腺癌患者和22例良性前列腺增生患者,因患有下尿路梗阻接受PVP治疗,分别于术前和术后取静脉血,用反转录PCR技术探测患者血液中的前列腺特异抗原(PSA)mRNA,以间接探测术后血液中是否有来自前列腺的上皮细胞。结果PVP治疗前列腺癌导致的下尿路梗阻过程中由于前列腺血管得到较好封闭,没有前列腺上皮细胞进入血液循环。结论应用PVP治疗前列腺癌不会导致前列腺癌细胞进入血液循环。 | 朱刚 Gordon H Muir | 2007 | 现代泌尿外科杂志2007，12，2： | 10 |
| 7 | 诊断性试验和策略的证据质量和推荐强度的分级显示文摘GRADE系统能对诊断性试验或策略的证据质量和推荐强度进行分级。本文旨在阐释在此过程中如何考虑患者的重要结局, | Holger J Schünemann Andrew D Oxman Jan Brozek Paul Glasziou Roman Jaeschke Gunn E Vist John W Williams Jr Regina Kunz Jonathan Craig Victor M Montori Patrick Bossuyt Gordon H Guyatt 李晓 黄程 陈耀龙 李幼平 | 2009 | 中国循证医学杂志2009，9，5： | 7 |
| 8 | 钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1受体激动剂治疗成人2型糖尿病:临床实践指南显示文摘临床问题对于存在不同心血管风险及肾脏结局的2型糖尿病患者,在原有生活方式干预和/或其他降糖药物的基础上加用钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂的获益及风险是什么?现行做法几十年来,2型糖尿病的治疗决策都以控制血糖为主导。SGLT-2抑制剂和GLP-1受体激动剂在传统观念中常被用于二甲双胍治疗后血糖仍控制不佳的患者。目前这一现状已经发生了改变,这得益于多项临床研究结果。研究显示SGLT-2抑制剂和GLP-1受体激动剂拥有独立于药物降糖作用之外的对于动脉粥样硬化性心血管病(CVD)和慢性肾脏病(CKD)的获益。建议本指南阐述了针对不同风险分层的成人2型糖尿病患者使用SGLT-2抑制剂或GLP-1受体激动剂的建议。•伴有3种或更少的心血管风险因素且不存在CVD或CKD:不建议启动SGLT-2抑制剂或GLP-1受体激动剂治疗。(推荐等级:弱)•伴有3种以上心血管风险因素且不存在CVD或CKD:建议启动SGLT-2抑制剂治疗,不建议启动GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD或CKD:建议启动SGLT-2抑制剂治疗和GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD和CKD:建议启动SGLT-2抑制剂治疗(推荐等级:强)和GLP-1受体激动剂治疗。(推荐等级:弱)•对于那些想要进一步降低CVD和CKD结局风险的患者:推荐优先启用SGLT-2抑制剂治疗而非GLP-1受体激动剂治疗。(推荐等级:弱)这项指南是如何制订的一个由患者、临床医生和方法学家共同组成的国际小组提出了这些推荐意见。这些推荐意见基于可信度较高的指南的标准,并使用GRADE分级方法进行评估。该小组采用了息者个体化的观点。证据一项关于获益与风险的系统综述和网络meta分析(764项随机对照研究,包括421346例参与者)发现SGLT-2抑制剂和GLP-1受体激动剂可以降低总体死亡率、心肌梗死发生率、终末期肾病或肾衰竭的发生率(中等至高等质量的证据)。在不同的亚组中这些药物对卒中、因心力衰竭所致住院和其他主要不良事件有不同的影响。药物绝对获益的程度因患者个体风险的不同有很大的差异。(例如,对于接受了超过5年药物治疗的1000例患者,在最低风险人群中死亡人数减少了5人,在最高风险人群中死亡人数减少了48人)。一项关于预后的综述确认了14种风险预测模型,其中一种(RECODe)在证据总结中报告了大部分基线风险评估数据,小组利用该模型以支持风险分层的建议。考虑到患者的价值观及个体差异,指南推荐的支撑证据包括一项对已发表论文的系统综述、一项患者焦点小组研究、一项临床问题总结,以及一项指南调查。指南解读我们依据不同的CVD和CKD风险水平,综合考虑获益、风险和其他因素的平衡,以及每一个风险组别的实际问题,来对推荐意见进行分层。本指南强烈建议CVD和CKD患者使用SGLT-2抑制剂治疗,这说明专家组认为其具有显著的获益。而对于其他成人2型糖尿病患者,推荐等级较弱,这说明专家组想要在获益、风险及治疗花费上取得一个更好的平衡。临床医生通过该指南可以使用可靠的风险计算模型,如RECODe,来明确其患者的个体心血管和肾脏疾病风险。医患交互式总结临床证据和制订决策有助于患者知晓治疗选择,包括进行共同决策。2型糖尿病人群(全球患病率不断增长1-2)正面临着不断增加的心血管疾病、肾脏病和其他并发症的风险3。数十年来,2型糖尿病的管理始终以控制血糖及糖化血红蛋白(HbA1c)为治疗目标4-5,但是,最近的高质量随机对照研究已经对这种以血糖为中心的治疗模式发起了挑战。研究结果显示,强化血糖控制未必会降低大血管不良事件,它还可能带来不利影响监管机构现在要求新型糖尿病药物必须证明其具有心血管和肾脏获益才能获得批准。对两类新药--钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂(见框图1)的临床试验结果显示,在现有治疗方案(常规治疗)之上加用这些药物,对死亡、心肌梗死、卒中、心力衰竭和肾脏的结局(如进展为终末期肾病)都有获益8-12。 | Sheyu Li Per Olav Vandvik Lyubov Lytvyn Gordon H Guyatt Suetonia C Palmer Rene Rodriguez-Gutierrez Farid Foroutan Thomas Agoritsas Reed A C Siemieniuk Michael Walsh Lawrie Frere David J Tunnicliffe Evi V Nagler Veena Manja Bjφrn Olav Asvold Vivekanand Jha Mieke Vermandere Karim Gariani Qian Zhao Yan Ren Emma Jane Cartwright Patrick Gee Alan Wickes Linda Fems Robin Wright Ling Li Qiukui Hao Reem A Mustafa 无 郭鹤鸣(译) | 2021 | 英国医学杂志中文版2021，24，9： | 7 |
| 9 | 循证实践中的医患选择——医疗决策不能迷信证据而要靠人显示文摘 | R Brain Haynes PJ Devereaux Gordon H Guyatt 陈霖 | 2003 | 中国循证医学杂志2003，3，4： | 7 |
| 10 | Drug eluting biliary stents to decrease stent failure rates:Areview of the literature显示文摘Biliary stenting is clinically effective in relieving both malignant and non-malignant obstructions. However, there are high failure rates associated with tumor ingrowth and epithelial overgrowth as well as internally from biofilm development and subsequent clogging. Within the last decade, the use of prophylactic drug eluting stents as a means to reduce stent failure has been investigated. In this review we provide an overview of the current research on drug eluting biliary stents. While there is limited human trial data regarding the clinical benefit of drug eluting biliary stents in preventing stent obstruction, recent research suggests promise regarding their safety and potential efficacy. | Joseph Shatzel Jisoo Kim Kartik Sampath Sharjeel Syed Jennifer Saad Zilla H Hussain Kabir Mody J Marc Pipas Stuart Gordon Timothy Gardner Richard I Rothstein | 2016 | World Journal of Gastrointestinal Endoscopy2016，8，2： | 6 |
| 11 | Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patients显示文摘AIM: To identify the rate of non-responders to clopidogrel treatment in hip fracture patients and study how non-responders differ from controls.METHODS: In a retrospective case-control study we included 28 cases of acute proximal femoral fracture with clopidogrel treatment 2011 to 2013. Eighty-four controls from the same time period were included. Data collected included response to clopidogrel measured with multiple electrode aggregometry(MEA), intraoperative bleeding, erythrocyte transfusion, time to surgery and the incidence of adverse events up to 3 mo after surgery. RESULTS: Eight(29%) of the 28 cases were nonresponders. The median intraoperative bleeding was 300 mL(range, 0-1500), and was lower for non-responders(50 m L) but did not reach statistical significance. Erythrocyte transfusions did not differ between responders, non-responders and controls. Forty-five(40%) of 112 patients had adverse events postoperatively but the rate did not differ between patients with and without clopidogrel treatment.CONCLUSION: Almost one-third of patients withclopidogrel treatment and an acute proximal femoral fracture are non-responders to antiplatelet therapy and can be operated without delay. | Anna Clareus Inga Fredriksson Hkan Wallén Max Gordon André Stark Olof Skldenberg | 2015 | World Journal of Orthopedics2015，6，5： | 4 |
| 12 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 13 | Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice显示文摘AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P < 0.001), and 11(3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340(41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most(94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients. | Shomron Ben-Horin Jane M Andrews Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein | 2017 | World Journal of Gastroenterology2017，23，16： | 3 |
| 14 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 15 | Small bowel adenocarcinoma and Crohn's disease: Any further ahead than 50 years ago?显示文摘This review of the literature on small bowel carcinoma associated with Crohn's disease specifically addresses the incidence, risk factors, and protective factors which have been identified. It also reviews the clinical presentation, the current modalities of diagnosis, the pathology, treatment, and surveillance. Finally, the prognosis and future direction are addressed. Our experience with small bowel adenocarcinoma in Crohn's disease is reported. Readers will be provided with a better understanding of this rare and often poorly recognized complication of Crohn's disease. | Caitlin Cahill Philip H Gordon Andrea Petrucci Marylise Boutros | 2014 | World Journal of Gastroenterology2014，20，33： | 2 |
| 16 | GRADE:在推荐分级中体现对资源利用的考虑显示文摘指南小组成员对资源利用是否会影响个体患者的治疗决策有不同看法。由于医疗费用上涨,必须考虑资源利用的影响,但指南小组成员可能会发现这有很大的挑战性。 | Gordon H Guyatt Andrew D Oxman Regina Kunz Roman Jaeschke Mark Helfand Alessandro Liberati Gunn E Vist Holger J Schьnemann 王菊芬 陈耀龙 李幼平 | 2009 | 中国循证医学杂志2009，9，6： | 2 |
| 17 | Prognostically relevant gene signatures of high-grade serous ovarian carcinoma显示文摘 | Verhaak Roel G W Tamayo Pablo Yang Ji-Yeon Hubbard Diana Zhang Hailei Creighton Chad J Fereday Sian Lawrence Michael Carter Scott L Mermel Craig H Kostic Aleksandar D Etemadmoghadam Dariush Saksena Gordon Cibulskis Kristian Duraisamy Sekhar | 2013 | Journal of Clinical Investigation2013，，1： | 2 |
| 18 | Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial显示文摘 | A David Mendelow Barbara A Gregson Helen M Fernandes Gordon D Murray Graham M Teasdale D Terence Hope Abbas Karimi M Donald M Shaw David H Barer | 2005 | 2005 (9457)2005，，9457： | 2 |
| 19 | WONCA研究论文摘要汇编——初级保健服务中慢性疼痛的自我管理障碍:一项基于专题小组讨论的定性研究显示文摘背景自我管理是被推崇的慢性疼痛干预方法。有效地自我管理可以减少疼痛对患者日常生活的影响。临床指南指出初级保健服务有助于慢性疼痛患者的自我管理。目的分析初级保健专业人员、慢性疼痛患者及其照顾者对慢性疼痛自我管理的意见,在此基础上探究不利于应用和开展慢性疼痛自我管理的因素。设计与场所此项定性研究在苏格兰开展,研究对象为数个专题小组。方法共有18个小组参与专题讨论,包括54名慢性疼痛患者、9名慢性疼痛患者的照顾者以及38名初级保健专业人员。结果通过分析各小组的观点,得出4类不利于慢性疼痛自我管理的因素:(1)不和谐的医患沟通:部分患者认为自我管理慢性疼痛已经为时过晚或者不重要。医生和患者很难沟通,难以构建良好的医患关系;(2)患者体验:由于没有设身处地地考虑慢性疼痛对患者情绪的影响,使得患者常觉得初级保健专业人员对他们的治疗不积极;(3)有限的治疗方案:一些研究对象感觉治疗有过度医疗化的倾向;(4)机构的组织管理缺点:医生用于诊疗患者的时间短,患者候诊时间长,以及英国国家医疗服务体系实行的分级诊疗带来的看病困难问题。结论此项研究分析了应用与开展慢性疼痛自我管理所面临的挑战。如果自我管理是治疗慢性疼痛的一种重要方法,初级保健专业人员需要找到解决不利因素的方法,以使其顺利应用与开展。 | GORDON K RICE H ALLCOCK N 本刊编辑部 | 2017 | 中国全科医学2017，20，12： | 2 |
| 20 | Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response显示文摘 | John M. Vierling Mitchell Davis Steven Flamm Stuart C. Gordon Eric Lawitz Eric M. Yoshida Joseph Galati Velimir Luketic Jonathan McCone Ira Jacobson Patrick Marcellin Andrew J. Muir Fred Poordad Lisa D. Pedicone Janice Albrecht Clifford Brass Anita Y.M. H | 2013 | Journal of Hepatology2013，，： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员